Abstract: Provided are cell based methods to identify memory modulating compounds based on the assessment of KIBRA expression. These methods are also suitable to uncover memory related pathways. The methods comprise the contacting of test compounds with cultured cells and the subsequent assessment of modulation of the KIBRA expression within the cells.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: An absorbent composition for removing CO2 and/or H2S from a gas comprising a polyamine, a monoamine and water, wherein the polyamine comprises a polyamine having 3 to 5 amine functions and has a molecular weight of less than 200 g/mol; wherein the monoamine comprises a tertiary monoamine; and wherein the weight ratio of the polyamine having 3 to 5 amine functions to the tertiary monoamine is more than 1:1. A process wherein such an absorbent composition is used and a use of a tertiary monoamine as an accelerator for accelerating the removal of CO2 and/or H2S from a CO2 and/or H2S containing polyamine having 3 to 5 amine functions.

Abstract: The present invention relates to a method of treating Amyotrophic Lateral Sclerosis by the targeted delivery of granulocyte-colony stimulating factor to the central nervous system with an adeno-associated virus (AAV) vector.

Abstract: The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis.

Abstract: The instant invention discloses a process for the preparation a polyolefin nanocomposite which comprises melt mixing a mixture of a polyolefin, a filler and a non-ionic surfactant.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to the use of tranilast and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and neuroregeneration. The invention furthermore relates to the use of tranilast and derivatives thereof for the in vitro differentiation of neuronal stem cells and the use of such pre-treated cells for stem cell therapy von neurological conditions.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The instant invention discloses a process for the preparation a polyolefin nanocomposite which comprises melt mixing a mixture of a polyolefin, a filler and a non-ionic surfactant.

Abstract: The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 ?g per kg body weight over a treatment period of about 3 days is suitable for the treatment of stroke. Treatment in accordance with the invention with a total dose of 80 to 150 ?g per kg body weight is preferred.

Abstract: The present invention is aimed at a method of providing wettability to polyester fibers or filaments, to woven or nonwoven fabrics made therefrom and to resultant articles of manufacture. The method comprises melt extruding a mixture comprising a polyester and one or more alkyl metal sulfonates where the metal is Na, Li or K and the alkyl is straight or branched chain alkyl of 1 to 24 carbon atoms, or is straight or branched chain alkenyl of 2 to 24 carbon atoms. The alkyl metal sulfonates are present from about 0.1% to about 1.9% by weight based on the weight of the polyester. A post treatment step such as an alkaline treatment step is not included. The melt extrusion mixtures do not include certain additives such as polyoxyalkylene compounds, alkylmonoethonolamide compounds, alkyldiethanolamine compounds and polyetheramide compounds.

Abstract: A trocar tube, trocar, obturator, rectoscope is suitable for transluminal endoscopic surgery via natural body cavities. A trocar tube (2) has a distal section (22) for positioning at least in the region of or outside the body cavity, and a proximal section (21) for positioning within the human or animal, wherein at least the proximal section has a substantially rigid or inflexible curvature. An obturator (3) and a rectoscope (5) may be adapted for use with such a trocar tube for this purpose.

Abstract: The instant invention relates to new compounds of the formula I R1 and R2 are each independently of the other a fluorine containing group, R3 and R4 are each independently of the other hydrogen, a fluorine containing group, C1-C12alkyl, phenyl or R4, together with the carbon atom to which they are bonded, form a C5-C8-cycloalkylidene ring that is unsubstituted or substituted by from 1 to 3 C1-C4alkyl groups; R5, R6, R7 and R8 are each independently of the other hydrogen, C1-C12alkyl or C3-C12alkenyl, X1 and X2 are each independently of the other a direct bond or C1-C12alkylene, m is 1 to 10,000, and n is 0 to 10,000. These new compounds of the formula I are useful as reducers of surface energy for organic materials such as polycarbonates, polyesters or polyketones or their mixtures, blends or alloys.

Abstract: The present invention relates to a method of treating neurological conditions in a mammal by administering a hematopoietic growth factor such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony stimulating factor (GMCSF). The invention also provides methods of screening for compounds that bind to a GCSF or GMCSF receptor found on the surface of a neuronal cell; and which provides a neuroprotective, neuroproliferative and/or a STAT gene activation activity.

Abstract: The present invention relates to the use of piperine and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and/or neuroregeneration. The invention furthermore relates to the use of piperine and derivatives thereof for the in vitro differentiation of neural stem cells and the use of such pre-treated cells for stem cell therapy von neurological conditions.

Abstract: The present invention relates to the compounds of formula I as well as to their use as PIM kinase inhibitors and, thereby, their use for treating oncological diseases, particularly of the hematopoietic system, the liver and the prostate gland.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.